The correct way and time to take brigatinib/brigatinib (Embry)

Brigatinib/Brigatinib (Brigatinib) is an oral targeted drug for ALK-positive advanced stagenon-small cell lung cancer. Its effect is closely related to the patient's medication method, dose adjustment, and timing. In order for the medicine to work more stably, it is usually recommended to take it according to a fixed procedure. Overseas data generally emphasize that brigatinib adopts an "increasing dose strategy", that is, 90 mg per day for the first 7 days, and then increased to 180 mg per day after tolerance is confirmed to help reduce the risk of early pulmonary discomfort and other reactions. Patients should maintain regularity when taking it and try to swallow the entire tablet at the same time every day. There is no need to chew or break it. It can be swallowed with warm water.

Brigatinib is a once-daily targeted drug. There are no strict regulations on the best time to take the drug, but it is medically recommended to fix it at a stable time in the morning or evening. The reason is that The 24-hour blood drug concentration curve needs to be stable, and a fixed time can reduce fluctuations and make it easier to observe the body's reaction. If you take other medications daily, you should communicate with your doctor in advance, especially those that affect gastric acid, to avoid affecting absorption. In terms of its relationship with food, brigatinib can be taken with meals or on an empty stomach, but a consistent method is more conducive to maintaining stable absorption, and patients can choose according to their own gastrointestinal status.

If a dose is missed, the principle is to take it as soon as possible. However, if the time before the next dose is less than 12 hours , it is not recommended to take additional doses to avoid dose superposition. For occasional gastric discomfort, you can choose to take it with meals to help reduce the burden, but you should not take the medicine immediately after a high-fat meal to avoid affecting the absorption rate.

In addition, you may experience slight respiratory discomfort, increased cough, or muscle soreness during the initial period of taking the medication. Overseas guidelines recommend maintaining early monitoring and promptly communicating with your doctor if any significant changes occur. Regular medication and static monitoring are important foundations for maintaining the efficacy of brigatinib.

Reference materials:https://www.alunbrig.com/